ω-3 fatty acid treatment in cardiac syndrome X: A double-blind, randomized, placebo-controlled clinical study

Coronary Artery Disease

Volumn 24, Issue 4, 2013, Pages 328-333

  Bozcali, Evin ^a   Babalik, Erhan ^b   Himmetoglu, Solen ^c   Mihmanli, Ismail ^d   Toprak, Sadik ^e  

^a Baltalimani Bone Diseases Education and Research Hospital   (Turkey)

^b Memorial Hospital   (Turkey)

^c Department of Biochemistry ^*  (Turkey)

^d ISTANBUL UNIVERSITY   (Turkey)

^e ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

Author keywords

Coronary resistance; Endothelial dysfunction; Lipid peroxidation; Microvascular angina; Oxidative stress

Indexed keywords

GLYCERYL TRINITRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL;

ADULT; ARTERY DIAMETER; ARTICLE; BRACHIAL ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY VASCULAR RESISTANCE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; FEMALE; HUMAN; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SYNDROME X; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VASODILATATION;

ADULT; BRACHIAL ARTERY; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; ISOSORBIDE DINITRATE; MALE; MALONDIALDEHYDE; MICROVASCULAR ANGINA; MIDDLE AGED; OXIDATIVE STRESS; TREATMENT OUTCOME; VASODILATION; VASODILATOR AGENTS;

EID: 84877049852     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0b013e32835f3005     Document Type: Article

References (42)

1. Kemp HG. Left ventricular function in patients with anginal syndrome and normal coronary arteriograms. Am J Cardiol 1973; 32:375-376.
2. Kemp HG, Kronmal RA, Vlietstra RE, Frye RL. Seven year survival of patients with normal or near normal coronary arteriograms: a CASS registry study. J Am Coll Cardiol 1986; 7:479-483.
3. Kaski JC, Crea F, Nihoyannopoulos P, Hackett D, Maseri A,Watson J, et al. Transient myocardial ischemia during daily life in patients with syndrome X. Am J Cardiol 1986; 58:1242-1247.
4. Kaski JC, Rosano GM, Collins P, Nihoyannopoulos P, Maseri A, Poole-Wilson PA. Cardiac syndrome X: clinical characteristics and left ventricular function: long-term follow-up study. J Am Coll Cardiol 1995; 25:807-814.
5. Gulati M, Cooper-DeHoff RM, McClure C, Johnson D, Shaw LJ, Handberg EM, et al. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from theWomen's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. Arch Intern Med 2009; 169:843-850.
6. Kaski JC. Pathophysiology and management of patients with chest pain and normal coronary arteriograms (cardiac syndrome X). Circulation 2004; 109:568-572.
7. Cannon RO 3rd. Microvascular angina and the continuing dilemma of chest pain with normal coronary angiograms. J AmColl Cardiol 2009; 54:877-885.
8. Lamendola P, Lanza GA, Spinelli A, Sgueglia GA, Di Monaco A, Barone L, et al. Long-term prognosis of patients with cardiac syndrome X. Int J Cardiol 2010; 140:197-199.
9. Shaw LJ, Merz CNB, Pepine CJ, Reis SE, Bittner V, Kip KE, et al. for the WISE investigators. Circulation 2006; 114:894-904.
10. Cannon RO 3rd, Epstein SE.'Microvascular angina' as a cause of chest pain with angiographically normal coronary arteries. Am J Cardiol. 1988;61:1338-1343.
11. Kaski JC, Elliott PM, Salomone O, Dickinson K, Gordon D, Hann C, et al. Concentration of circulating plasma endothelin in patients with angina and normal coronary angiograms. Br Heart J 1995; 74:620-624.
12. Egashira K, Inou T, Hirooka Y, Yamada A, Urabe Y, Takeshita A. Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina pectoris and normal angiograms. N Engl J Med 1993; 328: 1659-1664.
13. Bellamy MF, Goodfellow J, Tweddel AC, Dunstan FDJ, Lewis MJ, Henderson AH. Syndrome X and endothelial dysfunction. Cardiovasc Res 1998; 40:410-417.
14. Swan JW, Walton C, Godsland IF, Crook D, Oliver MF, Stevenson JC. Insulin resistance syndrome as a feature of cardiological syndrome X in non-obese men. Br Heart J 1994; 71:41-44.
15. Sakr SA, Abbas TM, Amer MZ, Dawood EM, El-Shahat N, Aal IA, et al. Microvascular angina. The possible role of inflammation, uric acid, and endothelial dysfunction. Int Heart J 2009; 50:407-419.
16. On YK, Park R, Hyon MS, Kim SK, Kwon YJ. Are low total serum antioxidant status and elevated levels of C-reactive protein and monocyte chemotactic protein-1 associated with cardiac syndrome X? Circ J 2005; 69: 1212-1217.
17. Kayikcioglu M, Saygi S, Azarsiz E, Can LH, Kultursay H, Sozmen EY. Serum paraoxonase 1 activity and oxidative markers of LDL in patients with cardiac syndrome X. Acta Cardiol 2007; 62:245-249.
18. Pizzi C, Manfrini O, Fontana F, Bugiardini R. Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cardiac syndrome X role of superoxide dismutase activity. Circulation 2004; 109:53-58.
19. Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF, et al. PPARa activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension 2002; 40:866-871.
20. Fleischhauer FJ, Yan WD, Fischell TA. Fish oil improves endotheliumdependent coronary vasodilation in heart transplant recipients. J Am Coll Cardiol 1993; 21:982-989.
21. Goodfellow J, Bellamy MF, Ramsey MW, Jones CJ, Lewis MJ. Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia. J Am Coll Cardiol 2000; 35:265-270.
22. Celermajer DS, Sorensen KE, Gooch VM, Spielgelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-1115.
23. Del Rio D, Stewart AJ, Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis 2005; 15:316-328.
24. Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Prodzinski J, McDonell M, et al. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol 1995; 25:333-341.
25. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer DS, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelialdependent flow-mediated vasodilatation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39:257-265.
26. Hurst T, Olson TH, Olson LE, Appleton CP. Cardiac syndrome X and endothelial dysfunction: new concepts in prognosis and treatment. Am J Med 2006; 119:560-566.
27. Cox ID, Botker HE, Bagger JP, Sonne HS, Kristensen BO, Kaski JC. Elevated endothelin concentrations are associated with reduced coronary vasomotor responses in patients with chest pain and normal coronary arteriograms. J Am Coll Cardiol 1999; 34:455-460.
28. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87:840-844.
29. Lim TK, Choy AJ, Khan F, Belch JJ, Struthers AD, Lang CC. Therapeutic development in cardiac syndrome X: a need to target the underlying pathophysiology. Cardiovasc Ther 2009; 27:49-58.
30. Erdamar H, Sen N, Tavil Y, Yazici HU, Turfan M, Poyraz F, et al. The effect of nebivolol treatment on oxidative stress and antioxidant status in patients with cardiac syndrome-X. Coron Artery Dis 2009; 20:238-244.
31. Tayyebi-Khosroshahi H, Houshyar J, Tabrizi A, Vatankhah AM, Razzagi Zonouz N, Dehghan-Hesari R. Effect of omega-3 fatty acid on oxidative stress in patients on hemodialysis. Iran J Kidney Dis 2010; 4:322-326.
32. Kesavulu MM, Kameswararao B, Ch Apparao, Kumar EG, Harinarayan CV. Effect of omega-3 fatty acids on lipid peroxidation and antioxidant enzyme status in type 2 diabetic patients. Diabetes Metab 2002; 28:20-26.
33. Garrel C, Alessandri JM, Guesnet P, Al-Gubory KH. Omega-3 fatty acids enhance mitochondrial superoxide dismutase activity in rat organs during post-natal development. Int J Biochem Cell Biol 2012; 44:123-131.
34. Allard JP, Kurian R, Aghdassi E, Muggli R, Royall D. Lipid peroxidation during n-3 fatty acid and vitamin E supplementation in humans. Lipids 1997; 32:535-541.
35. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26:1235-1241.
36. Neunteufl T, Heher S, Katzenschlager R,Wolfl G, Kostner K, Maurer G, et al. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 2000; 86:207-210.
37. Lekakis JP, Papamichael CM, Vemmos CN, Voutsas AA, Stamatelopoulos SF, Moulopoulos SD. Peripheral vascular endothelial dysfunction in patients with angina pectoris and normal coronary arteriograms. J Am Coll Cardiol 1998; 31:541-546.
38. Haberka M, Mizia-Stec K, Mizia M, Janowska J, Gieszcyk K, Chmiel A, et al. N-3 polyunsaturated fatty acids early supplementation improves ultrasound indices of endothelial function, but not through NO inhibitors in patients with acute myocardial infarction: N-3 PUFA supplementation in acute myocardial infarction. Clin Nutr 2011; 30:79-85.
39. Adams MR, Robinson J, McCredie R, Seale JP, Sorensen KE, Deanfield JE, et al. Smooth muscle dysfunction occurs independently of impaired endothelium-dependent dilation in adults at risk of at risk of atherosclerosis. J Am Coll Cardiol 1998; 32:123-127.
40. Kaptchuk TJ. Powerful placebo: the dark side of the randomized controlled trial. Lancet 1998; 351:1722-1725.
41. Kaptchuk TJ, Friedlander E, Kelley JM, Sanchez MN, Kokkotou E, Singer JP, et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One 2010; 5:e15591.
42. Vermeltfoort IA, Teule GJ, van Dijk AB, Muntinga HJ, Raijmakers PG. Long-term prognosis of patients with cardiac syndrome X: a review. Neth Heart J 2012; 20:365-371.